Editorial: JAK inhibition in autoimmune and inflammatory diseases

Front Immunol. 2022 Dec 28:13:1120281. doi: 10.3389/fimmu.2022.1120281. eCollection 2022.

¹ Inflammation and Immunology, Pfizer, Cambridge, MA, United States.
² Translational Immunology Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, United States.
³ Department of Dermatology, Venereology and Allergology, Charité-Universitätsmedizin Berlin, Berlin, Germany.
⁴ Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.
⁵ Dipartimento di Scienze Cliniche, Internistiche, Anestesiologiche e Cardiovascolari-Reumatologia, Sapienza Universitá di Roma, Roma, Italy.

No abstract available

Keywords: JAK; JAK - STAT signaling pathway; STAT (signal transducer and activator of transcription); autoimmune diseases; inflammatory disease.

Publication types